Braidwell LP Purchases New Shares in Hemab Therapeutics Holdings, Inc. $COAG

Braidwell LP acquired a new position in shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 160,000 shares of the company’s stock, valued at approximately $5,877,000. Braidwell LP owned about 0.34% of Hemab Therapeutics at the end of the most recent reporting period.

Insider Activity

In other news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Analyst Ratings Changes

A number of research analysts recently weighed in on COAG shares. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Evercore initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 target price on the stock. Weiss Ratings began coverage on Hemab Therapeutics in a report on Thursday, August 13th. They issued a “sell (d+)” rating for the company. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Finally, Jefferies Financial Group boosted their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Hemab Therapeutics Stock Performance

Shares of COAG stock opened at $44.70 on Thursday. The business’s 50 day moving average is $44.66. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.00 and a 12-month high of $55.42. The stock has a market cap of $2.09 billion and a price-to-earnings ratio of -1.80.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Equities research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current fiscal year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.